Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 8/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429987 | 0.85 | RXRA (0.46) | PDE3BPDE3ARXRAGRIN1GRIN2B | |
| SCHEMBL4425521 | 0.80 | P2RX7 (0.55) | PDE3BPDE3AALDH1A1MEN1LMNA | |
| SCHEMBL4427005 | 0.79 | PDE3B (0.44) | PDE3BPDE3ARXRAGRIN1GRIN2B | |
| SCHEMBL2173293 | 0.78 | PDE3B (0.50) | PDE3BPDE3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7671977 | 0.78 | LTA4H (0.46) | PDE3BPDE3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4428934 | 0.75 | MEN1 (0.42) | ALDH1A1MEN1LMNAHSP90AA1PKM | |
| SCHEMBL4432563 | 0.74 | NOTUM (0.51) | PDE3BPDE3ARXRAGRIN1GRIN2B | |
| SCHEMBL4434213 | 0.74 | NOTUM (0.51) | PDE3BPDE3ALMNACPB1CPB2 | |
| SCHEMBL3426575 | 0.74 | PDE3B (0.50) | PDE3BPDE3ALMNACYP1A2CYP3A4 | |
| SCHEMBL1698763 | 0.74 | PDE3B (0.50) | PDE3BPDE3ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683097-B2 | AFFINITY TO NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR SUBTYPE SELECTIVE BLOCKERS; MEDIATING PROCESSES UNDERLYING DEVELOPMENT OF CENTRAL NERVOUS SYSTEM AS WELL AS LEARNING AND MEMORY FORMATION | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667335-B2 | NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030187268-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6610723-B2 | Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020151715-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | GRIN1, GRIN2B, GRIN3B | PDE3B 2740/4885PDE3A 2511/4885RXRA 2410/4885 |
| US-20020151715-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | PDE3B 1701/4885PDE3A 1485/4885RXRA 2501/4885 |
| US-20030187268-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | PDE3B 1701/4885PDE3A 1485/4885RXRA 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.